ADC Therapeutics Past Earnings Performance
Past criteria checks 0/6
ADC Therapeutics's earnings have been declining at an average annual rate of -3.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 44.9% per year.
Key information
-3.9%
Earnings growth rate
6.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 44.9% |
| Return on equity | n/a |
| Net Margin | -300.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL
Dec 12Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
Nov 16
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Jul 18Limiting Concerns On ADC Therapeutics' Prospects
Jun 06ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues
May 30Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results
May 10ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
Sep 16ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Sep 09Revenue & Expenses Breakdown
How ADC Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 71 | -212 | 90 | -12 |
| 30 Jun 24 | 67 | -215 | 93 | 0 |
| 31 Mar 24 | 69 | -227 | 98 | -13 |
| 31 Dec 23 | 70 | -240 | 106 | 0 |
| 30 Sep 23 | 123 | -181 | 114 | 94 |
| 30 Jun 23 | 184 | -184 | 128 | 0 |
| 31 Mar 23 | 182 | -200 | 137 | 38 |
| 31 Dec 22 | 210 | -157 | 143 | 0 |
| 30 Sep 22 | 157 | -166 | 146 | 0 |
| 30 Jun 22 | 94 | -187 | 143 | 0 |
| 31 Mar 22 | 80 | -195 | 142 | 0 |
| 31 Dec 21 | 34 | -230 | 136 | 0 |
| 30 Sep 21 | 17 | -252 | 129 | 0 |
| 30 Jun 21 | 4 | -200 | 116 | 0 |
| 31 Mar 21 | 0 | -254 | 100 | 0 |
| 31 Dec 20 | 0 | -246 | 77 | 0 |
| 30 Sep 20 | 0 | -226 | 53 | 0 |
| 30 Jun 20 | 0 | -237 | 35 | 0 |
| 31 Mar 20 | 1 | -135 | 19 | 0 |
| 31 Dec 19 | 2 | -116 | 14 | 0 |
| 30 Sep 19 | 3 | -112 | 11 | 0 |
| 30 Jun 19 | 3 | -111 | 11 | 0 |
| 31 Mar 19 | 2 | -117 | 10 | 0 |
| 31 Dec 18 | 1 | -123 | 9 | 0 |
| 31 Dec 17 | 2 | -90 | 8 | 0 |
Quality Earnings: ADCT is currently unprofitable.
Growing Profit Margin: ADCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ADCT is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.
Accelerating Growth: Unable to compare ADCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: ADCT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 19:10 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ADC Therapeutics SA is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Lut Ming Cheng | Cantor Fitzgerald & Co. |
| Eric Schmidt | Cantor Fitzgerald & Co. |